M&A
-
Biopharma Firm Finalizes Takeover of French Immuno-Oncology Specialist
The international biopharmaceutical corporation, Ipsen, successfully concluded its purchase of ImCheck Therapeutics on December 15, 2025, in Paris, France. This…
Read More » -
Pharmaceutical Manufacturer Gaelic Labs Acquires Athlone Laboratories
Gaelic Laboratories, a pharmaceutical manufacturer specializing in Beta-Lactam (penicillin) products, has acquired Athlone Laboratories, a developer and manufacturer of oral…
Read More » -
Major Biotech Deal: Sobi Acquires Arthrosi in Transaction Valued Up to $1.5 Billion
On December 15, 2025, Swedish Orphan Biovitrum AB (Sobi), a global biopharma company based in Stockholm, announced that it has…
Read More » -
Mirum Pharmaceuticals Expands Portfolio With Bluejay Therapeutics Acquisition
Transaction Overview and Terms Mirum Pharmaceuticals Inc., a specialty pharmaceutical company focused on rare diseases, has reached an agreement to…
Read More » -
Viatris Exits Preferred Equity Stake in Biocon Biologics in Major Transaction
The global healthcare enterprise Viatris has executed definitive agreements for the divestiture of its entire convertible preferred equity holding in…
Read More » -
Sandoz Finalizes Acquisition of Just-Evotec Biologics EU SAS, Reinforcing Biosimilars Leadership
(Basel, December 8, 2025) – Sandoz Group AG (SIX: SDZ/OTCQX: SDZNY), the global leader in affordable medicines, announced the successful…
Read More » -
Pharma Megamerger: Major Drug Company Unifies $5.5 Billion Biologics Subsidiary
A major pharmaceutical company has announced the successful completion of a plan to fully integrate its Biologics subsidiary, officially making…
Read More » -
Minimum Acceptance Threshold Met in Exchange Proposal Between Two Biotech Firms
(MAINZ, Germany, December 3, 2025) – The biotech firm BioNTech (Nasdaq: BNTX) recently announced that the minimum condition for its…
Read More » -
Eli Lilly Secures Experimental Cancer Therapy from Scorpion in Up-to-$2.5 Billion Deal
Eli Lilly announced its plan to acquire an experimental cancer therapy from Scorpion Therapeutics for a total consideration of up…
Read More » -
📰 Novartis Acquires Anthos Therapeutics for Up to $3.1 Billion to Boost Cardiovascular Pipeline
The Swiss pharmaceutical giant Novartis has reached an agreement to acquire Anthos Therapeutics, a biopharmaceutical firm majority-owned by the life…
Read More » -
Merck Finalizes $3.4 Billion Acquisition, Enhancing Rare Tumor Portfolio
Merck has successfully completed its previously announced $3.4 billion acquisition of SpringWorks Therapeutics, a biopharmaceutical company based in Stamford, Connecticut.…
Read More » -
Roche Commits $3.5 Billion to Bolster MASH Portfolio via 89bio Acquisition
Roche has announced its plan to acquire 89bio, a San Francisco-based biotechnology firm, in a strategic move valued at approximately…
Read More » -
Novo Nordisk Secures Key MASH Therapy in $5.2 Billion Strategic Deal
Global pharmaceutical giant Novo Nordisk has significantly strengthened its position in the treatment landscape for Metabolic Dysfunction-associated Steatohepatitis (MASH) with…
Read More » -
Merck Finalizes $10 Billion Acquisition of Verona Pharma with No Competing Bids
Merck successfully completed its $10 billion acquisition of Verona Pharma last month, a deal notable for the absence of a…
Read More » -
Johnson & Johnson Expands Neuroscience Portfolio with $14.6 Billion Acquisition
Global healthcare leader Johnson & Johnson (J&J) commenced the J.P. Morgan Healthcare Conference by announcing its intent to acquire Intra-Cellular…
Read More » -
Pharmaceutical Giant Finalizes Acquisition of Obesity Drug Developer
The global pharmaceutical corporation Pfizer Inc. has announced the successful conclusion of its acquisition of the clinical-stage biotechnology firm, Metsera,…
Read More »
